NCT01568580View on ClinicalTrials.gov

Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A

PHASE3CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Hemophilia A
Interventions
DRUG

GreenGene

Dose : 10 \~ 50IU/kg Administration method : intravenous infusion or bolus

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY